BackSyndax Pharmaceuticals Overview

Syndax Pharmaceuticals Receivables

Latest receivables for SNDX: $70M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$70.16M
87.47% YoYΔ $32.73M vs prior year quarter

Peer trimmed avg / median

Loading

Syndax Pharmaceuticals Receivables History

Loading

Syndax Pharmaceuticals vs. peers: Receivables Comparison

Loading

Syndax Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Syndax Pharmaceuticals (SNDX) FAQ

As of the most recent data (June 2026), SNDX shows a receivables of $70M. That compares with $37M in the prior-year period — up 87.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SNDX's receivables is now $70M (was $37M) — a 87.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Syndax Pharmaceuticals is outperforming or lagging.

Tracking SNDX's receivables over time shows whether Syndax Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $70M That compares with $37M in the prior-year period — up 87.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Syndax Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $70M) with ownership activity and broader fundamentals.

Syndax Pharmaceuticals's receivables is $70M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.